avadel
present
oppenheimer
fall
healthcare
life
sciences
medtech
summit
dublin
ireland
globe
newswire
avadel
pharmaceuticals
plc
nasdaq
avdl
company
focused
developing
investigational
formulation
sodium
oxybate
today
announced
executive
team
presenting
oppenheimer
fall
healthcare
life
sciences
medtech
summit
taking
place
september
presentation
details
date
tuesday
september
time
et
webcast
live
archived
webcast
presentation
available
click
company
website
click
addition
management
participating
meetings
investors
registered
attend
conference
avadel
pharmaceuticals
plc
avadel
pharmaceuticals
plc
nasdaq
avdl
emerging
biopharmaceutical
company
company
primary
focus
development
fda
approval
investigational
formulation
sodium
oxybate
designed
treat
excessive
daytime
sleepiness
cataplexy
patients
narcolepsy
information
please
visit
investigational
formulation
cr
sodium
oxybate
march
company
completed
study
pivotal
randomized
phase
trial
assess
efficacy
safety
treatment
excessive
daytime
sleepiness
cataplexy
patients
suffering
narcolepsy
granted
orphan
drug
designation
food
drug
administration
fda
treatment
narcolepsy
designation
granted
plausible
hypothesis
may
clinically
superior
formulation
sodium
oxybate
already
approved
fda
indication
particular
may
safer
due
ramifications
associated
dosing
regimen
previously
approved
product
contacts
investor
contacts
tom
mchugh
chief
financial
officer
phone
email
tmchugh
tim
mccarthy
lifesci
advisors
llc
phone
email
tim
media
contact
patrick
bursey
lifesci
communications
llc
phone
email
pbursey
